Jose R. Conejo-Garcia

CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells.

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells.

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.

Vascular leukocytes contribute to tumor vascularization.

HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.

Immunotherapy for gynaecological malignancies.

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.

Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity.

Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer.

Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.

Role of vascular leukocytes in ovarian cancer neovascularization.

PILAR is a novel modulator of human T-cell expansion.

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.

CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

Nanomolecular targeting of dendritic cells for ovarian cancer therapy.

Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.

Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration.

Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors.

Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses.

Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.

Double agents in the war on cancer: leukocytes govern ovarian cancer progression.

Mast cells impair the development of protective anti-tumor immunity.

Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?

Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy.

Editorial: A clear vision needs some balance.

Anti-tumor immunity: myeloid leukocytes control the immune landscape.

Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles.

Avirulent Toxoplasma gondii Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment.

Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.

A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis.

Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.

Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer.

Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors.